ArticleFrontiers in oncology2024
Machine learning-driven survival prediction in gestational trophoblastic neoplasms: a focus on PSTT and ETT prognosis.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of a Machine Learning‑Based Prognostic Model for Intermediate Trophoblastic Tumors: A Single-Center Study With Web-Based Tool Implementation.JCO precision oncology · 2026Article
- Outcomes in gestational and non-gestational choriocarcinoma: A retrospective cohort study with nomograms and web tools.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The clinicopathological characteristics and prognosis of placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) have not been well summarized. Consequently, we conducted the largest to date series of samples of both types and employed machine learning (ML) to assess treatment effectiveness and develop accurate prognostic models for patients with GTN. Gestational choriocarcinoma (GCC) was used as the control group to show the clinical features of PTSS and ETT. Methods: The Surveillance, Epidemiology, and End Results (SEER) database provided the data used for this study's analysis. To identify the prognostic variables, we conducted Cox regression analysis and constructed prognostic models using five ML algorithms to predict the 5-year survival. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to validate the accuracy and reliability of the ML models. We also investigated the role of multiple therapeutic options using the Kaplan-Meier survival analysis. Results: The study population comprised 725 patients. Among them, 139 patients had ETT, 107 had PSTT, and 479 had GCC. There were no significant differences in survival between the different tumor groups. Multivariate Cox regression analysis revealed that metastasis was a significant prognostic factor for GCC, while older age and radiotherapy were significant prognostic factors for PTSS and ETT. ML models revealed that the Gradient Boosting classifier accurately predicted the outcomes, followed by the random forest classifier, K-Nearest Neighbors, Logistic Regression, and multilayer perceptron models. The most significant contributing factors were tumor size, year of diagnosis, age, and race. Discussion: Our study provides a method for treatment and prognostic assessment of patients with GTN. The ML we developed can be used as a convenient individualized tool to facilitate clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.